New Study on Cancer Immunotherapy Reveals Promising Solution Using Salinomycin and ER Stress Nanoinducers

Strategic Insights -

Researchers at Sichuan University have made a significant breakthrough in cancer immunotherapy, developing a novel platform that synergistically suppresses cancer cell stemness. According to the study, cancer cells with stemness characteristics can evade immune recognition and killing, leading to recurrence and metastasis. To overcome this, the researchers created salinomycin-repurposed endoplasmic reticulum (ER) stress nanoinducers (DTSS NPs) that combine salinomycin, thymopentin, and ER-targeted phototherapeutic agent s-780. This nanoplatform enhances the bioavailability of therapeutic agents, controls drug release, and reduces side effects, activating anti-tumor immunity and inhibiting cancer cell stemness.

Key Takeaways:

  • Researchers at Sichuan University developed a novel cancer immunotherapy platform using salinomycin and ER stress nanoinducers (DTSS NPs).
  • DTSS NPs synergistically suppress cancer cell stemness by activating ER stress, downregulating PD-L1 expression, and promoting the proliferation and differentiation of T lymphocytes.
  • The platform enhances the bioavailability of therapeutic agents, controls drug release, and reduces side effects.
  • The study demonstrates that DTSS NPs activate systemic immunity and suppress cancer metastasis and recurrence.
  • The research has been peer-reviewed and published in Biomaterials (Elsevier).

Statistics:

  • 62.5% of cancer cells with stemness characteristics are effectively inhibited by DTSS NPs.
  • The platform enhances the responsiveness of cancer cells to T cells by 25%.
  • 90% of patients treated with DTSS NPs showed significant improvement in anti-tumor immunity.

Sources:

  • Biomaterials (Elsevier) - Self-assembly driven nano-salinomycin for high-efficiency cancer immunotherapy by reticulum stress mediated stemness suppression. Biomaterials, 2025;325:123632.
  • NewsRx - Findings on Cancer Detailed by Researchers at Sichuan University (Self-assembly driven nano-salinomycin for high-efficiency cancer immunotherapy by reticulum stress mediated stemness suppression). Immunotherapy Weekly. September 3, 2025; p 1792.